- All
- Europe
- US
- All
- Educational Events
- Webinars
- Corporate Events
- Conferences
- All
- AFIRMA®
- DECIPHER®
- ENVISIA®
- PROSIGNA®
- BIOPHARMA SERVICES
- IVD SERVICES
Boston, MA
Take the opportunity to meet our team in Boston during the 6th Annual Next-Gen Immuno-Oncology Conference which address the challenges and future directions in Immuno-Oncology research. The Veracyte Biopharma services will discuss with you how they can translate the complex tumor immune response into a clear path forward to help you advance your therapeutic discovery, development and commercialization programs.
If you would like to meet with the Veracyte team during the 6th Annual NGIO Conference, please book an in-person or virtual meeting.
Chicago, IL
Visit us at the ENDO 2023 Annual Meeting and learn how the largest gene and fusion panel available has become part of Afirma GSC, along with the added capability of TERT DNA analysis.
Data being presented during the conference:
Thursday, June 15th 12:30-1:30 PM CT
Dr. Sina Jasim is presenting a poster titled, “Cytologic and Molecular Assessment of Isthmus Thyroid Nodules.”
Location: THU-680
Saturday, June 17th 8:00-9:30 AM CT
Managing Lumps and Bumps in the Thyroid
Dr. Joshua Klopper will participate in a panel discussion about “the use of various molecular tests and markers to distinguish and stratify patients with benign and malignant nodules” as part of the “Managing Lumps and Bumps in the Thyroid” session.
Location: W-181
Saturday, June 17th 1:00-2:00 PM CT
Dr. Priyanka Iyer is presenting a poster titled, “Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay.”
Location: SAT-630
Sunday, June 18th 8:00-9:30 AM CT
Predicting Thyroid Malignancy: What Tools Do We Have?
Dr. Allan Golding will be presenting a study titled, “mRNA Expression Based Tumor Behavior Prediction Models in Thyroid Nodules.”
Location: W-176
We will be available at booth #1509 to answer any questions.
Boston, MA
We are pleased to meet you in Boston during the BIO International Convention. Our Biopharma Services team is dedicated to helping our biopharma partners advance precision medicine in the era of immuno-oncology and combination therapies.
If you would like to meet with the Veracyte team during the BIO International Convention, please book an in-person or virtual meeting using the link below.
We invite you to join our live discussion looking at how intrinsic molecular subtypes can help guide therapeutic decisions.
The presentation will be supported by clinical case discussions with:
- Pr Frédérique Penault-Llorca
- Pr Gilles Freyer
- Dr Olivier Tredan
Bordeaux, France
Meet with us in Bordeaux at Meet2Win to learn how our Biopharma Services team can help you confidently advance every step of your therapeutic discovery, development and commercialization programs.
If you would like to meet with the Veracyte team during Meet2Win, please schedule an in-person or virtual meeting via the link below.
Berlin, Germany
Onsite and virtual
Meet our team in Berlin to learn how Prosigna Breast Cancer Assay was developed from the four PAM50 intrinsic subtypes and provides better prognostic accuracy.
If you would like to book a meeting with the Veracyte team during ESMO Breast, please use the BOOK A MEETING link below.
Virtual
Meet our team to learn how our Biopharma Services team can help you to confidently advance every step of your oncology drug development programs.
If you would like to book a meeting with the Veracyte team during Biotechgate Digital Partnering, please use the BOOK A MEETING link below.
Seattle, WA
Visit us at the AACE Annual Meeting and learn how the largest gene and fusion panel available has become a part of Afirma GSC with the added capability of TERT DNA analysis.
Jessica Pinto, MD will present a poster titled “Histopathology of Telomerase Reverse Transcriptase
Promoter (TERT) Mutated Indeterminate Thyroid Nodules” on Friday, May 5, 2023 from 10:25 am – 10:40 am PT. Location: The Poster Experience - Summit Building - Level 2.
In addition, there are other opportunities to engage with the Afirma team:
Join us for a cocktail reception on Friday, May 5th from 5:00 – 7:00 pm PT at The Nest Rooftop Bar (110 Stewart Street, Seattle WA 98101), as we recognize the positive impact of molecular testing on patients with thyroid nodules.
We will be available at booth #220 to answer any questions.
Veracyte will be present at the 2023 American Association of Endocrine Surgeons (AAES) annual meeting.
Visit us at the AAES meeting and learn how Afirma genomic testing can help you confidently guide surgery and treatment decisions for your patients with thyroid nodules.
Orlando, FL
Join us at the AACR Annual Meeting 2023 to learn more about how Veracyte’s Biopharma Services offerings can help you move your oncology and immuno-oncology drug development programs forward with confidence. We invite you to book an in-person meeting in advance or connect with us in Orlando at any of the following:
-
Attend our Spotlight Theater on Sunday, April 16th, 3:30-4:30 PM ET, “Leveraging multi-omics insights to advance drug development programs”. Meet our speakers from Veracyte (Jérôme Galon, PhD, Senior VP and Scientific Executive Director Veracyte, Corinne Danan, General Manager, Biopharma Services at Veracyte, Jacques Fieschi, PhD, VP, Research Discovery at Veracyte) and users of our services who will share how Decipher GRID Real-World Data, Biopharma Atlas and Immunogram can help guide your drug development programs.Book Your Seat Today
Visit our poster presentations featuring several of our technologies:
- Deciphering the tumor microenvironment at single-cell resolution using a workflow combining RNA transcript and protein detection with Brightplex®, a sequential chromogenic multiplex assay.
- Presenter: Jacques Fieschi, Ph.D., Veracyte
- Date/Time: Tuesday, April 18, 1:30-5:00 p.m. ET
- Location: Poster Section 4 (Poster #14, Abstract #4624)
- Veracyte Biopharma Atlas for colorectal cancer: combining multi-parameter approach and machine learning to capture the complexity of the tumor immune contexture.
- Presenter: Florence Monville, Ph.D., Research Discovery, Veracyte
- Date/Time: Tuesday, April 18, 1:30-5:00 p.m. ET
- Location: Poster Section 37 (Poster #26, Abstract #5476)
- Defining the cancer Immunogram using multimodal analysis to guide immunotherapy in diffuse large B cell lymphoma.
- Presenter: Régis Perbost, Ph.D., Veracyte and Mike Mattie, Ph.D., Kite a Gilead company
- Date/Time: Wednesday, April 19, 9:00 a.m.-12:30 p.m. ET
- Location: Poster Section 4 (Poster #21, Abstract #5879)
Speak with a Biopharma Services team member at Booth #1701
March 20–22, 2023 | Basel, Switzerland
March 28–30, 2023 | Digital
Meet with us to learn more about Veracyte's powerful databases and analytics capabilities that enable biopharmaceutical companies to gain actionable insights to confidently advance every step of their oncology and immuno-oncology drug development programs.
If you would like to meet with the Veracyte team during Bio Europe Spring, please book an in-person or virtual meeting.
Vienna, Austria
Visit us at booth #13 during the St.Gallen International Breast Cancer Conference 2023 to learn how the Prosigna Breast Cancer Assay was developed from the four PAM50 intrinsic subtypes and provides better prognostic accuracy and improves treatment decisions.
If you would like to book a meeting with the Veracyte’s Prosigna team, please submit a request and we will be in touch.
London, UK
Meet with us in London to learn how our Biopharma Services team can help you confidently advance your oncology drug development programs. If you would like to meet with the Veracyte team during Next-Gen Immuno-Oncology Conference, please book an in-person or virtual meeting.
We are also delighted to host a presentation at the meeting entitled, "The Veracyte Biopharma Atlas, A Comprehensive Cancer Reference Database," with Valérie Balme, Ph.D., Associate Director, Business Development for Biopharma Services at Veracyte.
Don’t miss this presentation and the opportunity to learn more about the Veracyte Biopharma Atlas and how it can help clinical researchers maximize the value of the data generated through our Immunogram analysis platform.
Miami Beach, FL
Visit us at booth #1 to learn about the new US Prosigna patient report and how the Prosigna Gene Signature Assay provides more comprehensive information to better inform treatment decisions.
If you would like to book a meeting with Veracyte’s Prosigna team, please submit a request and we will be in touch.
San Francisco & Online
Meet with our Decipher Urologic Cancers and Biopharma Services teams at ASCO GU!
We will be at Booth #46 throughout the conference. Come join us to learn more about our Decipher Prostate and Decipher Bladder genomic classifiers, as well as how our Decipher GRID RWD offering can help support biopharma partners in their drug development program
Brooklyn, NY
Meet with our Biopharma Services team in New York at Immuno-Oncology 360° to learn how you can gain actionable insights to confidently advance your oncology and immuno-oncology drug development programs.
If you would like to meet with the Veracyte team during Immuno-Oncology 360° , please book an in-person or virtual meeting.Virtual
Meet with our Biopharma Services team to learn how we can help you confidently advance every step of your oncology drug development programs.
If you would like to book a meeting with the Veracyte team during Biotechgate Digital Partnering, please submit a request.Visit us at booth #724 to learn how the Prosigna Gene Signature Assay provides more comprehensive information to better inform treatment decisions.
If you would like to book a meeting with the Veracyte team at SABCS, please submit a request and we will be in touch.
Montreal, Quebec, Canada
Visit us at the ATA meeting and learn how Afirma genomic testing can help you confidently guide surgery and treatment decisions for patients with thyroid nodules. Data being presented at the meeting include:
-
Visit us at the ATA meeting and learn how Afirma genomic testing can help you diagnose and create the best treatment plan for your patients with thyroid nodules. Data being presented at the meeting include:
- John Phay, MD presenting a study titled “Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules (ITN) Harboring Thyroid Stimulating Hormone Receptor (TSHR) Mutations” on Friday, October 21st. This presentation will be within the session titled “Friday Afternoon Clinical Oral Abstracts - Pediatrics, Thyroid Nodules and Goiter” from 2:45pm – 4pm EDT
- Joshua Klopper, MD presenting a poster titled “Thyroid Nodule Risk Stratification: mRNA Expression Based Tumor Behavior Prediction Models” on Thursday, October 20th. This poster will be within the late breaking posters from 10:30am – 4:30pm.
In addition, there are other opportunities to engage with the Afirma team:
-
- Join us for a cocktail reception on Thursday, Oct 20th from 6:30-8:30pm at Sauvage (52 Rue Saint-Jacques), as we recognize the positive impact of molecular testing on patients with thyroid nodules - Create a reminder on your calendar
- We will be available at booth #911 to answer any questions. If you would like to book a meeting with the Afirma team, please submit a request and we will be in touch. Book a meeting
New Orleans, LA
Visit us at the CAP meeting and learn how Veracyte’s products can help you and your patients.
- Join us for a cocktail reception on Sunday, October 9th, from 6:30 - 8:30pm CDT as we recognize the positive impact of molecular testing on patients with thyroid nodules - Create a reminder on your calendar
- We will be available at our booth to answer any questions. If you would like to book a meeting with the Afirma team, please submit a request we will be in touch. Book a meeting
- Understand the history and origin of PAM50 & Prosigna
- Discuss their evolution from the laboratory to the clinic
- Learn how accurate biological classification can be used to best treat your patients
Philadelphia, PA
Visit us at the AAO-HNSF meeting and learn how Afirma genomic testing can help you confidently guide surgery and treatment decisions for patients with thyroid nodules.
- Join us for a cocktail reception on Sunday September 11th, from 6:30-8:30pm EDT in The Gallery in the Le Meridien hotel, as we celebrate the impact of molecular testing on patients with thyroid nodules. Create a reminder on your calendar
- We will be available at booth #2011 to answer any questions. If you would like to book a meeting with the Afirma team, please submit a request we will be in touch. Book a meeting
Visit us at booth #417 to learn more about Veracyte's portfolio of diagnostic products.
If you would like to book a meeting to meet with the Veracyte team at ESMO, please submit a request and we will be in touch.
- Understand the potential of Prosigna
- Discuss the advantages of using a second-generation genomic test
- Learn about the utility of intrinsic subtyping in the clinic
Join us at ENDO 2022, Booth #1238, and learn how Afirma genomic testing can help you confidently guide surgery and treatment decisions for patients with thyroid nodules.
Visit us at booth #21085 to learn more about Veracyte's portfolio of diagnostic products.
If you would like to book a meeting to meet with the Veracyte team at ASCO, please submit a request and we will be in touch: BOOK A MEETING
Visit us at the AAES meeting and learn how Afirma genomic testing can help you confidently guide surgery and treatment decisions for patients with thyroid nodules. We will be available at booth #102 to answer any questions. If you would like to book a meeting with the Afirma team, you can submit a request using the link below and we will be in touch.
Book a meeting
Veracyte has also sponsored an on demand webinar. Listen as Joshua Klopper, MD discusses the clinical performance of the Afirma Genomic Sequencing Classifier and how it can help optimize thyroid nodule management. The webinar can be accessed using the link below:
San Franscisco, California
Visit us at Booth 1908 to learn about our genomic diagnostic tests of interstitial lung disease and lung cancer. LEARN MORE
Join our ATS Industry Theaters
- Tuesday, May 17, 12:30-1:00pm - Integrating Novel Genomic Data to Improve ILD Dagnositc and Prognostic Confidence
- Tuesday, May 17, 1:30-2:00pm - Integrating the Percepta Genomic Sequencing Classifier for Lung Nodules and Risk Stratification
Data Presentation
- Monday, May 16, 9:30-11:00am - Poster #217: A Nasal Genomic Classifier for Assessing Risk of Malignancy In Lung Nodules Demonstrates Similar Performance In Patients that Meet Screening Criteria for High Baseline Risk and Those Who Do Not
San Diego, California
Visit us at the AACE meeting and learn how Afirma genomic testing can help you confidently guide surgery and treatment decisions for patients with thyroid nodules.
Data Presentations
- Saturday, May 14, 10:10am - Dorota Whitmer, MD will present a poster titled “Malignancy Risk Associated with the Thyroid Stimulating Hormone Receptor (TSHR) pI568T Variant in Bethesda III/IV Thyroid Nodule Cytology”
- Saturday May 14, 12:30pm - Joshua Klopper, MD will present “Clinical Performance of the Afirma Genomic Sequencing Classifier: Real World Experience and the Optimization of Thyroid Nodule Management”
Additional opportunities to engage with the Afirma team
- Friday May 13 Cocktail Reception, 5:00-7:00pm in the Presidential Suite (#3001) of the AACE conference hotel, the Hilton San Diego Bayfront, as we celebrate the impact of molecular testing on patients with thyroid nodules - Create a reminder on your calendar
- If you would like to book a meeting with the Afirma team, please submit a request we will be in touch. Book a meeting
Visit us at ESMO Breast 2022 to learn more about how Prosigna provides more comprehensive information combining tumor gene expression, clinico-pathological factors and intrinsic subtypes to better inform treatment decisions.
Dallas, Texas
Visit us at the AHNS annual meeting and learn how Afirma genomic testing can help you confidently guide diagnosis, and guide surgery and treatment decisions for patients with thyroid nodules.
We will be available at booth #501 to answer any questions.
A new on-demand webinar, sponsored by Veracyte, is available via the American Thyroid Association (ATA). Watch as a multidisciplinary panel from leading institutions across the country discusses the expanding role of tumor genotyping in thyroid nodule patient management. This discussion, led by Dr. Paul Ladenson, features several real-world case studies from the perspectives of an endocrinologist, surgeon, and pathologist.
This interactive session covers the key elements of an MDD, the role of the Envisia genomic classifier, and the identification of progressive fibrosing ILD.
Experts review how the Percepta and Envisia genomic classifiers help improve confidence in lung disease diagnosis and share how the tests integrate into their patient management.